Touchlight is an innovation-driven leading CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution.
Joined September 2021
- Tweets 549
- Following 106
- Followers 325
- Likes 40
354 Photos and videos
Jun 11
Plasmid DNA has long been central to cell and gene therapy development. As manufacturing demands scale, many developers are re‑evaluating whether pDNA is still the best fit for speed, consistency, and long‑term resilience. Get insights in this Q&A article eu1.hubs.ly/H0w5g7H0
24
Jun 9
We’re heading to #BIO2026! Meet the Touchlight team in the UK Pavilion at Booth #2221, & learn how cell‑free DNA manufacturing is helping customers overcome challenges in genetic medicines. Learn more or schedule a meeting today here: eu1.hubs.ly/H0w1rsl0
21
Jun 8
Producing high-quality RNA is essential for the success of #RNA-based therapeutics. This application note explores how IVT template quality may impact RNA purity, dsRNA content, and manufacturing consistency. Get the insights, access it here: eu1.hubs.ly/H0v_w1y0 #cellfreedna
27
Jun 5
Stay up-to-date on Cell Therapy trends. Subscribe to our 'Cell-Free Insights' newsletter & get the insights and innovative solutions in genetic medicine, delivered straight to your inbox. Stay ahead of the curve here: eu1.hubs.ly/H0vYV9P0
25
Jun 3
dbDNA™ technology eliminates biological limitations, ensuring high-purity, scalable DNA synthesis. Using enzymatic processes, Touchlight can deliver optimised DNA vectors to help bring cutting-edge genetic applications to fruition quickly. Explore here: eu1.hubs.ly/H0vV6db0
39
Jun 2
Genetic medicines need a DNA infrastructure built for scale. Join Touchlight's CSO Jill Makin and Will Downie as they discuss why cell-free DNA is emerging as critical infrastructure for the future of genetic medicine.👉 Register here: eu1.hubs.ly/H0vShMq0
27
Jun 1
Gene editing workflows still face difficult tradeoffs between HDR efficiency, toxicity, and scalability. Explore how novel (ssDNA) payload architectures are helping researchers rethink non-viral gene editing. Get the expert insights here: eu1.hubs.ly/H0vPfMD0
30
May 29
Whether you’re developing gene therapies, mRNA vaccines, or cell-based treatments, our technologies provide speed, purity & flexibility you need to advance your program from discovery to commercialisation. Let us help move your program forward, faster: eu1.hubs.ly/H0vLYLJ0
38
May 27
With higher HDR efficiency, lower toxicity and scalable production,mbDNA™ is a breakthrough in non-viral, single-stranded DNA (ssDNA) technology. Reset your benchmark for gene therapy innovation. Get the expert insights here: eu1.hubs.ly/H0vGFFG0
26
May 26
We’re heading to #BIO2026! Meet the Touchlight team in the UK Pavilion at Booth #2221, & learn how cell‑free DNA manufacturing is helping customers overcome challenges in genetic medicines. Learn more or schedule a meeting today here: eu1.hubs.ly/H0vF5rm0
1
1
34
May 21
Non-viral delivery workflows continue to push the limits of plasmid DNA systems. This analysis explores how alternative DNA architectures may improve in vivo protein expression and durability in non-viral delivery applications. Access it here: eu1.hubs.ly/H0vxP050
28
May 19
Producing high-quality RNA is essential for the success of #RNA-based therapeutics. This application note explores how IVT template quality may impact RNA purity, dsRNA content, and manufacturing consistency. Get the insights, access it here: eu1.hubs.ly/H0vscHs0 #cellfreedna
35
May 18
LVV manufacturing timelines continue to slow many cell & gene therapy programs. Plasmid workflows can introduce variability, complexity, and scale-up challenges. Explore strategies for streamlining LVV production and accelerating path-to-clinic timelines: eu1.hubs.ly/H0vq1_w0
26
May 15
Gene editing workflows often force tradeoffs between HDR efficiency, toxicity, and scalability. Explore how mbDNA™ may help researchers improve non-viral ssDNA editing workflows and overcome limitations of traditional templates. Read the article: eu1.hubs.ly/H0vm1jt0
42
May 14
At #ASGCT26, Touchlight and @SartoriusGlobal shared new insights into how mbDNA™ and non-viral delivery solutions may improve editing outcomes. Visit booth #1334 today explore our 3 posters on display. Get all the details and book a meeting here: eu1.hubs.ly/H0vkMwB0
1
68
May 13
Whether you’re developing gene therapies, mRNA vaccines, or cell-based treatments, our technologies provide speed, purity & flexibility you need to advance your program from discovery to commercialisation. Let us help move your program forward, faster: eu1.hubs.ly/H0vjjDg0
46
May 12
Where does plasmid DNA still win, and where does cell-free DNA outperform? Watch as experts break down real-world data and what it means for next-generation gene therapy. Get the insights today in this on-demand webcast. eu1.hubs.ly/H0vggD60
39
May 12
We’re bringing new science, trending data, & big ideas to #ASGCT! Hear the latest cell-free DNA advancements, during the event, visit our 3 posters & hear an oral Presentation on Lipid-Based Formulations for Cell Free single stranded delivery on 5/13: eu1.hubs.ly/H0vgs0Q0
1
68
May 11
Join us at #ASGCT2026 this week! Touchlight is on site at booth 1334. Come see how our cell‑free DNA technologies are helping developers move faster and overcome the limitations of plasmid DNA. Learn more or request a meeting: eu1.hubs.ly/H0vcgyQ0 #DNAManufacturing
1
61
May 8
Touchlight will be exhibiting at booth 1713 at #ISCT2026 in Dublin (6–9 May). Don't miss our abstract presentation: “Reimagining DNA payloads; enzymatic circular DNA for the next generation of cell and gene therapies.” Request a meeting here: eu1.hubs.ly/H0v7l5s0
37